Phase III CELESTIMO data show Lunsumio regimen significantly improves progression-free survival in follicular lymphoma.
Why it matters
Phase III CELESTIMO data show Lunsumio regimen significantly improves progression-free survival in follicular lymphoma. — impact context not separately stored; see What changed.